An effort spearheaded by the US Food and Drug Administration to assess the technical reproducibility of next-generation sequencing platforms should begin generating data before the end of the year, with publication of results targeted for next spring, a project organizer told In Sequence.
FDA's SEQC Expands to Six Studies; RNA-seq Technical Reproducibility Work to Begin by Year End
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.